Flubendazole as potential anti-neuroblastoma therapy option

An abstract of a study by Michaelis et al on flubendazole as potential anti-neuroblastoma therapy option is presented. The study tested flubendazole for anti-cancer in cancer cell lines and in the chick chorioallantoic membrane assay. Protein levels were determined by Western blot and flow cytometry...

Full description

Saved in:
Bibliographic Details
Published inEuropean journal of cancer (1990) Vol. 69; p. S47
Main Authors Michaelis, M, Agha, B, Rothweiler, F, Loeschmann, N, Voges, Y, Westermann, F, Wass, M, Cinatl, J
Format Journal Article
LanguageEnglish
Published Oxford Elsevier Science Ltd 01.12.2016
Subjects
Biotechnology
Cancer
Cancer therapies
Chorioallantoic membrane
Cytometry
Flow cytometry
Gene expression
Hematology, Oncology and Palliative Medicine
Membrane proteins
Neuroblastoma
Proteins
Ribonucleic acid
RNA
RNA-mediated interference
Therapy
Tumor cell lines
Tumors
Viability
Online AccessGet full text

Cover

More Information
Summary:An abstract of a study by Michaelis et al on flubendazole as potential anti-neuroblastoma therapy option is presented. The study tested flubendazole for anti-cancer in cancer cell lines and in the chick chorioallantoic membrane assay. Protein levels were determined by Western blot and flow cytometry, while RNAi-mediated depletion was used to inhibit gene expression. Results indicate neuroblastoma identified as highly flubendazole-sensitive cancer entity in a screen of 321 cell lines from 26 cancer entities. Flubendazole also reduced the viability of five primary neuroblastoma samples in nanomolar concentrations thought to be achievable in humans and inhibited vessel formation and neuroblastoma tumour growth in the chick chorioallantoic membrane assay.
ISSN:0959-8049
1879-0852
DOI:10.1016/S0959-8049(16)32725-3